Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 148.54 Million EUR | -20.71% |
| 2022 | 182.7 Million EUR | -14.38% |
| 2021 | 213.39 Million EUR | -16.72% |
| 2020 | 256.24 Million EUR | 217.95% |
| 2019 | 80.59 Million EUR | -36.19% |
| 2018 | 126.29 Million EUR | -5.52% |
| 2017 | 133.66 Million EUR | -2.41% |
| 2016 | 136.97 Million EUR | -6.89% |
| 2015 | 147.1 Million EUR | 29.16% |
| 2014 | 113.9 Million EUR | 6.49% |
| 2013 | 106.95 Million EUR | 5.03% |
| 2012 | 101.83 Million EUR | -9.45% |
| 2011 | 112.46 Million EUR | 4.62% |
| 2010 | 107.49 Million EUR | 35.32% |
| 2009 | 79.43 Million EUR | 20.05% |
| 2008 | 66.17 Million EUR | 40.07% |
| 2007 | 47.24 Million EUR | 10.29% |
| 2006 | 42.83 Million EUR | 8994.48% |
| 2005 | 471 Thousand EUR | -29.6% |
| 2004 | 669 Thousand EUR | -98.4% |
| 2003 | 41.79 Million EUR | 27.12% |
| 2002 | 32.87 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 39.77 Million EUR | 9.88% |
| 2024 Q1 | 36.2 Million EUR | -4.88% |
| 2024 Q3 | 43.64 Million EUR | 9.73% |
| 2023 FY | 144.86 Million EUR | -20.71% |
| 2023 Q1 | 31.85 Million EUR | -34.62% |
| 2023 Q2 | 44.32 Million EUR | 39.16% |
| 2023 Q3 | 34.3 Million EUR | -22.59% |
| 2023 Q4 | 38.06 Million EUR | 10.93% |
| 2022 FY | 182.7 Million EUR | -14.38% |
| 2022 Q1 | 49.39 Million EUR | -38.79% |
| 2022 Q3 | 39.98 Million EUR | -10.36% |
| 2022 Q2 | 44.6 Million EUR | -9.7% |
| 2022 Q4 | 48.71 Million EUR | 21.82% |
| 2021 Q3 | 41.61 Million EUR | -9.02% |
| 2021 FY | 213.39 Million EUR | -16.72% |
| 2021 Q1 | 45.32 Million EUR | 4.59% |
| 2021 Q2 | 45.74 Million EUR | 0.91% |
| 2021 Q4 | 80.7 Million EUR | 93.91% |
| 2020 Q2 | 67.86 Million EUR | -30.32% |
| 2020 FY | 256.24 Million EUR | 217.95% |
| 2020 Q4 | 43.33 Million EUR | -9.05% |
| 2020 Q1 | 97.39 Million EUR | 341.24% |
| 2020 Q3 | 47.64 Million EUR | -29.78% |
| 2019 Q2 | 20.66 Million EUR | 13.9% |
| 2019 Q4 | 22.07 Million EUR | 12.02% |
| 2019 Q1 | 18.14 Million EUR | -18.18% |
| 2019 FY | 80.59 Million EUR | -36.19% |
| 2019 Q3 | 19.7 Million EUR | -4.66% |
| 2018 Q3 | 22.59 Million EUR | -52.72% |
| 2018 Q4 | 22.17 Million EUR | -1.83% |
| 2018 FY | 126.29 Million EUR | -5.52% |
| 2018 Q1 | 33.74 Million EUR | 9.13% |
| 2018 Q2 | 47.78 Million EUR | 41.6% |
| 2017 Q1 | 34.32 Million EUR | 2.03% |
| 2017 Q4 | 30.92 Million EUR | -2.98% |
| 2017 Q3 | 31.87 Million EUR | -12.79% |
| 2017 FY | 133.66 Million EUR | -2.41% |
| 2017 Q2 | 36.54 Million EUR | 6.46% |
| 2016 Q4 | 33.64 Million EUR | -5.41% |
| 2016 FY | 136.97 Million EUR | -6.89% |
| 2016 Q3 | 35.57 Million EUR | -1.27% |
| 2016 Q2 | 36.02 Million EUR | 13.56% |
| 2016 Q1 | 31.72 Million EUR | -41.16% |
| 2015 FY | 147.1 Million EUR | 29.16% |
| 2015 Q3 | 29.98 Million EUR | -16.34% |
| 2015 Q1 | 27.37 Million EUR | 5.2% |
| 2015 Q2 | 35.83 Million EUR | 30.92% |
| 2015 Q4 | 53.91 Million EUR | 79.84% |
| 2014 Q4 | 26.02 Million EUR | -10.24% |
| 2014 Q2 | 31.85 Million EUR | 17.8% |
| 2014 Q1 | 27.03 Million EUR | 6.67% |
| 2014 FY | 113.9 Million EUR | 6.49% |
| 2014 Q3 | 28.99 Million EUR | -8.98% |
| 2013 Q2 | 29.59 Million EUR | 23.88% |
| 2013 Q1 | 23.88 Million EUR | -52.49% |
| 2013 FY | 106.95 Million EUR | 5.03% |
| 2013 Q4 | 25.34 Million EUR | -9.91% |
| 2013 Q3 | 28.13 Million EUR | -4.92% |
| 2012 Q2 | 28.41 Million EUR | 18.18% |
| 2012 Q4 | 50.27 Million EUR | 93.08% |
| 2012 FY | 101.83 Million EUR | -9.45% |
| 2012 Q1 | 24.04 Million EUR | -56.08% |
| 2012 Q3 | 26.04 Million EUR | -8.35% |
| 2011 Q1 | 25.31 Million EUR | 7.26% |
| 2011 Q4 | 54.74 Million EUR | 92.95% |
| 2011 FY | 112.46 Million EUR | 4.62% |
| 2011 Q3 | 28.37 Million EUR | -10.9% |
| 2011 Q2 | 31.84 Million EUR | 25.77% |
| 2010 FY | 107.49 Million EUR | 35.32% |
| 2010 Q3 | 29.01 Million EUR | -4.99% |
| 2010 Q2 | 30.53 Million EUR | 25.45% |
| 2010 Q1 | 24.34 Million EUR | 44.74% |
| 2010 Q4 | 23.6 Million EUR | -18.65% |
| 2009 Q2 | 25.56 Million EUR | 68.02% |
| 2009 Q3 | 21.84 Million EUR | -14.55% |
| 2009 Q4 | 16.81 Million EUR | -23.01% |
| 2009 FY | 79.43 Million EUR | 20.05% |
| 2009 Q1 | 15.21 Million EUR | -2.81% |
| 2008 Q1 | 13.73 Million EUR | 0.0% |
| 2008 Q3 | 16.64 Million EUR | -17.3% |
| 2008 FY | 66.17 Million EUR | 40.07% |
| 2008 Q4 | 15.65 Million EUR | -5.97% |
| 2008 Q2 | 20.13 Million EUR | 46.52% |
| 2007 FY | 47.24 Million EUR | 10.29% |
| 2006 FY | 42.83 Million EUR | 8994.48% |
| 2005 FY | 471 Thousand EUR | -29.6% |
| 2004 FY | 669 Thousand EUR | -98.4% |
| 2003 FY | 41.79 Million EUR | 27.12% |
| 2002 FY | 32.87 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Atrys Health, S.A. | 52.61 Million EUR | -182.32% |
| Biotechnologies Assets SA | 3.45 Million EUR | -4195.743% |
| Laboratorios Farmaceuticos Rovi, S.A. | 492.28 Million EUR | 69.826% |